ABIO vs. ICCC, AWH, VNRX, OCX, TKNO, CDIO, TRIB, ACHV, ADEX, and RMTI
Should you be buying ARCA biopharma stock or one of its competitors? The main competitors of ARCA biopharma include ImmuCell (ICCC), Aspira Women's Health (AWH), VolitionRx (VNRX), OncoCyte (OCX), Alpha Teknova (TKNO), Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), Achieve Life Sciences (ACHV), Adit EdTech Acquisition (ADEX), and Rockwell Medical (RMTI). These companies are all part of the "medical" sector.
ARCA biopharma (NASDAQ:ABIO) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.
ARCA biopharma has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.
56.4% of ARCA biopharma shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 30.9% of ARCA biopharma shares are owned by insiders. Comparatively, 6.3% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
ARCA biopharma has a net margin of 0.00% compared to ImmuCell's net margin of -18.31%. ImmuCell's return on equity of -15.21% beat ARCA biopharma's return on equity.
In the previous week, ImmuCell had 3 more articles in the media than ARCA biopharma. MarketBeat recorded 6 mentions for ImmuCell and 3 mentions for ARCA biopharma. ARCA biopharma's average media sentiment score of 0.57 beat ImmuCell's score of 0.20 indicating that ARCA biopharma is being referred to more favorably in the media.
ARCA biopharma has higher earnings, but lower revenue than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than ARCA biopharma, indicating that it is currently the more affordable of the two stocks.
ARCA biopharma received 2 more outperform votes than ImmuCell when rated by MarketBeat users. However, 73.33% of users gave ImmuCell an outperform vote while only 42.27% of users gave ARCA biopharma an outperform vote.
Summary
ARCA biopharma beats ImmuCell on 9 of the 14 factors compared between the two stocks.
Get ARCA biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ARCA biopharma Competitors List
Related Companies and Tools
